Real-World Effectiveness of Pentavalent Rotavirus Vaccine among Bedouin and Jewish Children in Southern Israel

Clinical Infectious Diseases

Volumn 62, Issue , 2016, Pages S155-S160

  Leshem, Eyal ^a,b   Givon Lavi, Noga ^c   Tate, Jacqueline E ^b   Greenberg, David ^c   Parashar, Umesh D ^b   Dagan, Ron ^c  

^a TEL AVIV UNIVERSITY   (Israel)

^b NATIONAL CENTER FOR IMMUNIZATION AND RESPIRATORY DISEASES   (United States)

^c BEN GURION UNIVERSITY OF THE NEGEV   (Israel)

Author keywords

acute gastroenteritis; Bedouin; Israel; rotavirus; vaccine effectiveness

Indexed keywords

ROTAVIRUS VACCINE; LIVE VACCINE; VACCINE;

ACUTE GASTROENTERITIS; ARTICLE; BEDOUIN; CHILD; CONTROLLED STUDY; DRUG EFFICACY; EMERGENCY WARD; ENZYME IMMUNOASSAY; ETHNICITY; FECES ANALYSIS; FEMALE; GENOTYPE; HOSPITALIZATION; HUMAN; INFANT; ISRAEL; JEW; LABORATORY TEST; MAJOR CLINICAL STUDY; MALE; PRESCHOOL CHILD; PRIORITY JOURNAL; ROTAVIRUS INFECTION; SEASON; VACCINATION; VIRUS DIAGNOSIS; ARAB; ETHNOLOGY; FECES; GASTROENTERITIS; HOSPITAL EMERGENCY SERVICE; IMMUNOLOGY; PREVENTIVE HEALTH SERVICE; ROTAVIRUS; ROTAVIRUS INFECTIONS; STATISTICS AND NUMERICAL DATA; VACCINE IMMUNOGENICITY; VIROLOGY;

ARABS; CHILD, PRESCHOOL; EMERGENCY SERVICE, HOSPITAL; FECES; FEMALE; GASTROENTERITIS; GENOTYPE; HOSPITALIZATION; HUMANS; IMMUNIZATION PROGRAMS; IMMUNOGENICITY, VACCINE; INFANT; ISRAEL; JEWS; MALE; ROTAVIRUS; ROTAVIRUS INFECTIONS; ROTAVIRUS VACCINES; VACCINATION; VACCINE POTENCY; VACCINES, ATTENUATED;

EID: 84965145946     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/civ1012     Document Type: Article

References (18)

1. Parashar UD, Burton A, Lanata C, et al. Global mortality associated with rotavirus disease among children in 2004. J Infect Dis 2009; 200 (suppl 1):S9-15.
2. Vesikari T, Matson DO, Dennehy P, et al. Safety and efficacy of a pentavalent human-bovine (WC3) reassortant rotavirus vaccine. N Engl J Med 2006; 354:23-33.
3. Armah GE, Sow SO, Breiman RF, et al. Efficacy of pentavalent rotavirus vaccine against severe rotavirus gastroenteritis in infants in developing countries in sub-Saharan Africa: A randomised, double-blind, placebo-controlled trial. Lancet 2010; 376:606-14.
4. Zaman K, Dang DA, Victor JC, et al. Efficacy of pentavalent rotavirus vaccine against severe rotavirus gastroenteritis in infants in developing countries in Asia: A randomised, double-blind, placebo-controlled trial. Lancet 2010; 376:615-23.
5. Cortese MM, Immergluck LC, Held M, et al. Effectiveness of monovalent and pentavalent rotavirus vaccine. Pediatrics 2013; 132:e25-33.
6. Payne DC, Boom JA, Staat MA, et al. Effectiveness of pentavalent and monovalent rotavirus vaccines in concurrent use among US children <5 years of age, 2009-2011. Clin Infect Dis 2013; 57:13-20.
7. Staat MA, Payne DC, Donauer S, et al. Effectiveness of pentavalent rotavirus vaccine against severe disease. Pediatrics 2011; 128:e267-75.
8. Vesikari T, Uhari M, Renko M, et al. Impact and effectiveness of RotaTeq(R) vaccine based on 3 years of surveillance following introduction of a rotavirus immunization program in Finland. Pediatr Infect Dis J 2013; 32:1365-73.
9. Mast TC, Khawaja S, Espinoza F, et al. Case-control study of the effectiveness of vaccination with pentavalent rotavirus vaccine in Nicaragua. Pediatr Infect Dis J 2011; 30:e209-15.
10. Patel M, Pedreira C, De Oliveira LH, et al. Association between pentavalent rotavirus vaccine and severe rotavirus diarrhea among children in Nicaragua. JAMA 2009; 301:2243-51.
11. Givon-Lavi N, Ben-Shimol S, Cohen R, Greenberg D, Dagan R. Rapid impact of rotavirus vaccine introduction to the National Immunization plan in southern Israel: comparison between 2 distinct populations. Vaccine 2015; 33:1934-40.
12. Dagan R, Bar-David Y, Sarov B, et al. Rotavirus diarrhea in Jewish and Bedouin children in the Negev region of Israel: epidemiology, clinical aspects and possible role of malnutrition in severity of illness. Pediatr Infect Dis J 1990; 9:314-21.
13. Israel Central Bureau of Statistics. Population by district, sub-district and religion. Available at: http://www1.cbs.gov.il/reader/shnaton/shnatone-new.htm? CYear=2010&Vol=61&CSubject=2. Accessed 21 May 2014.
14. Givon-Lavi N, Greenberg D, Dagan R. Comparison between two severity scoring scales commonly used in the evaluation of rotavirus gastroenteritis in children. Vaccine 2008; 26:5798-801.
15. Gouvea V, Glass RI, Woods P, et al. Polymerase chain reaction amplification and typing of rotavirus nucleic acid from stool specimens. J Clin Microbiol 1990; 28:276-82.
16. Snelling TL, Andrews RM, Kirkwood CD, Culvenor S, Carapetis JR. Case-control evaluation of the effectiveness of the G1P[8] human rotavirus vaccine during an outbreak of rotavirus G2P[4] infection in central Australia. Clin Infect Dis 2011; 52:191-9.
17. Snelling TL, Schultz R, Graham J, et al. Rotavirus and the indigenous children of the Australian outback: monovalent vaccine effective in a high-burden setting. Clin Infect Dis 2009; 49:428-31.
18. Leshem E, Lopman B, Glass R, et al. Distribution of rotavirus strains and strainspecific effectiveness of the rotavirus vaccine after its introduction: A systematic review and meta-analysis. Lancet Infect Dis 2014; 14:847-56.